Home About Us Industry Report Store Resources Contact us

Neurodegenerative Disease Treatment Market To Reach USD 92891.87 Million By Year 2032

Neurodegenerative Disease Treatment Market Size Was Valued at USD 50019.88 Million in 2023 and is Projected to Reach USD 92891.87 Million by 2032, Growing at a CAGR of 7.12% From 2024-2032.

Swati Kalagate
Pristine Intelligence LLP

According to a new report published by Pristine Intelligence LLP, titled, “Neurodegenerative Disease Treatment Market by Indication, Drug Type, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2024–2032,” the Global Neurodegenerative Disease Treatment market size was valued at USD 50019.88 Million in 2023, and is projected to reach USD 92891.87 Million by 2032, registering a CAGR of 7.12% from 2024 to 2032. Medical approaches and interventions for neurodegenerative diseases aim to manage and slow down the progression of nerve-related disorders causing neuronal decay and impairment.

Neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's have the potential to significantly affect a person's quality of life through symptom reduction and enhanced overall wellness. The goal of treatment is to slow down the progression of symptoms and improve cognitive and physical abilities with different interventions. Rehabilitation programs aim to enhance mobility and foster independence. Current studies are looking for fresh approaches to treatment and methods to alter the course of diseases for upcoming advancements.

The growing number of elderly individuals worldwide is causing a rise in neurodegenerative conditions such as Alzheimer's and Parkinson's, putting pressure on healthcare systems and economies. Steps are being taken to enhance care for the elderly, promote early detection, and improve access to treatment. The increasing need for creative treatments spurs research, investments, and the advancement of personalized medicine tactics like targeted therapies and genetic testing.

The treatment of neurodegenerative diseases incurs high costs from expensive medications and ongoing care, resulting in significant healthcare expenses such as specialist appointments, tests, devices, and caregiving assistance. Assistive tools, adjustments to the home, and professional assistance also contribute to expenses. Having restricted availability of treatment causes increased costs for managing these illnesses.

Improvements in imaging techniques, biomarker analysis, and genetic testing facilitate the early detection of neurodegenerative diseases. Tailored treatment plans utilizing genetic information, disease characteristics, and biomarker analysis enhance the range of available therapeutic approaches. Telehealth and remote monitoring decrease the need for face-to-face appointments. Technological advancements improve the delivery of specific drugs, gene therapy, stem cell treatments, and neurostimulation.

Global Neurodegenerative Disease Treatment Market, Segmentation

The Neurodegenerative Disease Treatment market is segmented based on Indication, Drug Type, Route of Administration, Distribution Channel, and region.

Disease Indication:

Alzheimer's disease is a common neurodegenerative condition that impacts a large number of people globally, and there is currently no cure for it. Treatment is centered on controlling symptoms, and there is a growing need for treatments specifically aimed at Alzheimer's. As the elderly population increases, more cases are anticipated to emerge.

There is an increasing focus on studying and funding new treatments for Alzheimer's disease, resulting in a wider range of treatment choices. The consequences of the disease reach beyond individuals to include healthcare systems, families, and society, highlighting the importance of effective treatments in managing the challenges related to caregiving, healthcare expenses, and reduced productivity.

Drug Type:

Aberrant immune reactions and inflammation in the central nervous system are associated with neurodegenerative diseases. Immunomodulatory medications control the immune system to decrease inflammation, slow down the advancement of diseases, and safeguard neuronal cells. Thorough research has resulted in the creation of safer, more targeted medications with reduced side effects.

Immunomodulatory medications are increasingly accessible due to regulatory approvals and efforts to commercialize, leading to market expansion. They attend to autoimmune conditions and offer hope for healing neurodegenerative illnesses such as Parkinson's and Alzheimer's.


The advanced healthcare infrastructure in North America facilitates extensive research and development for innovative treatments for neurodegenerative diseases. The increased occurrence of these illnesses in the area leads to a notable need in the market, prompting more studies and advancements. Big pharmaceutical companies that specialize in neurodegenerative diseases are heavily involved in North America, supporting cooperation and financial backing. The large elderly population in the area is also a factor in the expansion of the market for treating neurodegenerative diseases in North America.

Some of The Active Market Players Are-

    • Hoffmann-La Roche (Switzerland)
    • Acadia Pharmaceuticals Inc. (USA)
    • AbbVie Inc (USA)
    • Alector, Inc. (USA)
    • Anavex Life Sciences Corp. (USA)
    • BioArctic (Sweden)
    • Biogen (USA)
    • Denali Therapeutics (USA)
    • Eisai Co., Ltd. (Japan)
    • Novartis (Switzerland)
    • Teva Pharmaceutical Industries (Israel)
    • Sanofi (France)
    • UCB (Belgium)
    • Lundbeck (Denmark)
    • Acorda Therapeutics (USA), and Other Active Players.

Key Industry Developments

    • March 2024: PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, announced the initiation of a ground-breaking pivotal trial. The "Celeste Light for PD Trial" at lightforpd.com is a major advancement in treating Parkinson's disease (PD), using Spectramax™ technology in the Celeste® phototherapy device, which is passive and non-invasive.
    • January 2024: AD-RIDDLE consortium announced that they will begin a new initiative that aims to bridge the gap between Alzheimer’s research, implementation science, and precision medicine. Alzheimer’s disease represents a major public health challenge. The AD-RIDDLE platform will allow for flexible adaptation and application in diverse settings, from memory clinics to primary care and the broader population outside of healthcare systems.

Key Findings of the Study 

    • The increased global geriatric population also increases the prevalence of diseases such as Alzheimer's and Parkinson's.   
    • Technological advancements like imaging techniques (MRI, PET scans), biomarker analysis, and genetic testing, have improved the ability to detect neurodegenerative diseases at early stages.
    • Alzheimer's disease is the most common neurodegenerative disorder which leads to affects a large number of individuals globally, leading to a higher demand for treatments specific to Alzheimer's disease.
    • North America has a relatively higher prevalence of neurodegenerative diseases, creating a significant market demand for effective treatment options.
Pristine Intelligence LLP

Conatct Us

Would you like to get in touch? We'll be happy to talk!

Press Contact